Home/Guidelines
|
Posted 14/08/2015
Until now generics have been required to be pharmaceutically equivalent and bioequivalent to the brand-name drug, however, generics made by different manufacturers could differ substantially from their brand-name therapeutic equivalents and from each other in their physical appearance, e.g. colour, shape or size of pills. The US Food and Drug Administration (FDA), aims to change this, with guidance issued in June 2015 recommending that the physical properties, including the size, shape and colour, of generics should be similar to those of their reference drugs.